New pill targets rare cancer gene in 30-Patient trial
NCT ID NCT07359820
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the drug shrinks tumors and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lirafugratinib (a targeted oral drug that blocks FGFR2)
- What this could lead to
- If it works, this could offer a new treatment option for people with certain hard-to-treat cancers that have an FGFR2 gene change.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FGFR2 GENE FUSION/REARRANGEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, 21079, France
-
Centre Leon Berard
NOT_YET_RECRUITINGLyon, 69373, France
-
Gustave Roussy Cancer Campus
NOT_YET_RECRUITINGParis, 94805, France
-
Hospital Universitario Fundación Jiménez Díaz- START MADRID
NOT_YET_RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro-START MADRID-CIOCC
NOT_YET_RECRUITINGMadrid, 28050, Spain
-
Institut Bergonie
NOT_YET_RECRUITINGBordeaux, 33076, France
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Mayo Clinic
NOT_YET_RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic
NOT_YET_RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
START Barcelona-Hospital HM Nou Delfos
NOT_YET_RECRUITINGBarcelona, 08023, Spain
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Sarah Cannon Research Institute UK
NOT_YET_RECRUITINGLondon, W1G 6AD, United Kingdom
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
The Christie NHS Foundation
NOT_YET_RECRUITINGManchester, M20 4GJ, United Kingdom
-
The University of Texas M.D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University College Hospital (NIHR UCLH Clinical Research Facility)
NOT_YET_RECRUITINGLondon, NW1 2BU, United Kingdom
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?